跳至主要内容
临床试验/NCT02183896
NCT02183896撤回不适用

Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip

University of Colorado, Denver1 个研究点 分布在 1 个国家开始时间: 2014年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
MRI dGEMRIC

研究概览

简要总结

The purpose of this research project is to assess the effectiveness of intra-articular injections of autologous platelet-rich plasma (PRP) after arthroscopic microfracture. Our hypothesis is that platelet-rich plasma will improve patient's clinical outcomes and chondral healing following microfracture performed during femoroacetabular impingement (FAI) hip arthroscopy.

详细描述

The purpose of this research project is to assess the effectiveness of intra-articular injections of autologous platelet-rich plasma (PRP) after arthroscopic microfracture. Our hypothesis is that platelet-rich plasma will improve patient's clinical outcomes and chondral healing following microfracture performed during femoroacetabular impingement (FAI) hip arthroscopy.

This study has two aims:

  1. Evaluate clinical efficacy of intra-articular injections of platelet-rich plasma (PRP) following arthroscopic microfracture.
  2. Evaluate if microfracture followed by PRP injections improves chondral healing.

Microfracture has shown good results with chondral lesions of the hip. However, microfracture does not regenerate normal hyaline cartilage. There is growing evidence that PRP can improve articular cartilage healing. Injection of PRP following microfracture may help regeneration to normal hyaline like articular cartilage together with soft tissue healing, thereby improving patients' early and long-term outcomes of chondral healing.

Patients will be randomized to one of two study arms - microfracture with PRP (treatment arm) and microfracture with saline (control arm) in a 1:1 ratio.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female patients aged 18-50, inclusive.
  • Healthy patients undergoing hip arthroscopy due to FAI.
  • No OA according to X-Ray, defined by the presence of joint space narrowing, osteophytes, sclerosis and subchondral cysts and surgery observation (Tonnis grade 0-1).
  • No other influential disabilities in lower limbs, which could alter the post-operative therapy.
  • No chronic use of NSAIDs, steroids, or chemotherapy drugs during the last 6 months before enrollment.
  • Women of childbearing potential will be allowed to enroll but must be willing to practice one highly effective method of contraception (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device [IUD] or intrauterine system [IUS] condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinence) throughout the study.
  • Intra-articular cartilage lesion grade 2-3-4-5 of Beck Classification or III-IV of Outerbridge.

排除标准

  • Patients with autoimmune concomitant disease(s) that may affect joints, such as rheumatoid arthritis (RA), psoriatic arthritis and lupus arthritis.
  • Patients with polyarticular disease.
  • Patients with major conditions, such as poorly controlled diabetes, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) or untreated depression.
  • Patients with blood disorders (thrombopathy, thrombocytopenia, anemia with hemoglobin <9g/dL).
  • Patients who had intra-articular treatment with steroids within 6 months of enrollment in this study or received more than 3 previous intra-articular steroid injections to the effected hip.
  • Patients who are pregnant or nursing at the time of consent.
  • Non-English speaking patients. (Scores used for evaluation have not been validated in Spanish).
  • Patients who had previous hip surgery.
  • Additional disabilities in any of the lower limbs that would interfere with any of the clinical assessments.
  • Chronic use of NSAIDs (defined as taking NSAID regularly every week for the last 6 months), steroids or chemotherapy drugs.
  • Patients with a BMI over
  • Due to the fact that this study utilizes an injection technique, which may be inaccurate in obese subjects.
  • Patients with pacemakers or metal implants who are unable to get an MRI.
  • Non-adherence according to inclusion criteria.
  • Patients allergic to lidocaine

研究组 & 干预措施

Platelet-rich plasma (PRP)

Experimental

Intra-articular injections in the hip of autologous platelet-rich plasma (PRP) at week 1 and 2 post-operatively. Dose 5 mL. PRP is derived from the patient's own blood.

干预措施: Platelet-rich plasma (PRP) (Biological)

Saline

Placebo Comparator

Intra-articular injections in the hip of saline, solution week 1 and 2 post-operatively. Dose: 5 mL at each injection.

干预措施: Saline (Drug)

结局指标

主要结局

MRI dGEMRIC

时间窗: 12 and 24 months post-operative

MRI dGEMRIC will be utilized to assess chondral healing. Change is being assessed between measurement time points.

次要结局

  • Non-arthritic hip score(Pre-operative; and 3, 6, 12, and 24 month post-operative)
  • Western Ontario and McMaster (WOMAC) osteoarthritis index(Pre-operative; and 3, 6, 12, and 24 month post-operative)
  • Flexion Abduction and External Rotation (FABER)(Pre-operative; prior to injections at week 1 and 2 post-operative; 6 week, and 3, 6, 12, and 24 months post-operative)
  • Bicycle Kicks(Pre-operative; prior to injections at week 1 and 2 post-operative; 6 week, and 3, 6, 12, and 24 months post-operative)
  • PA Hip X-Ray(Baseline, 12 and 24 months post-operative)
  • International Hip Outcome Tool (IHOT)(Pre-operative; and 3, 6, 12, and 24 month post-operative)
  • Range of Motion (ROM)(Pre-operative; prior to injections at week 1 and 2 post-operative; 6 week, and 3, 6, 12, and 24 months post-operative)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验